Search results
Results from the WOW.Com Content Network
This vaccine is a 2 or 3 dose series, depending on the brand of the vaccine, that is given at 2 and 4 months in the 2 dose series and at 2,4 and 6 months in the 3 dose series. Studies show that this vaccine is 85-98% effective against severe rotavirus disease and is 74-87% effective against rotavirus disease of any severity in the first year ...
Chin-Hong said if symptoms are mild, including low-grade fever, dry cough, sore throat, headaches and mild aches and pains, parents can keep their children home and contact their primary care ...
The Tdap vaccine (to help protect against whooping cough) is recommended during pregnancy. Other vaccines, like the flu shot, can be given before or during pregnancy, depending on whether or not it is flu season. Vaccination is safe right after giving birth, even while breastfeeding. [47] [48] [49] [50]
Booster shots can also be used after infections. In this regard, the UK's National Health Service recommends people to wait 28 days after testing positive for COVID-19 before getting their booster shots. Evidence shows that getting a vaccine after recovery from a COVID-19 infection provides added protection to the immune system. [28]
Anyone of age 6 months and up is eligible for an updated COVID-19 vaccine, which, like the flu shot, is reformulated each year to better match circulating variants. Experts say that groups such as ...
Fever, muscle aches, persistent and strong coughing, frequent sneezing with large amount of nasal discharge, or frequent vomiting and diarrhea warrant skipping a holiday gathering, according to ...
Six to nine days following exposure to adenovirus, one or both eyes, typically in children, may be affected in association with fever, pharyngitis and lymphadenopathy (pharyngoconjunctival fever (PCF)). [2] The onset is usually sudden, and there is often rhinitis. [5] Adenovirus infection can also cause adenoviral keratoconjunctivitis. [5]
“A serogroup B meningococcal (MenB) vaccine series may be administered to adolescents and young adults 16 through 23 years of age to provide short term protection against most strains of serogroup B meningococcal disease. The preferred age for MenB vaccination is 16 through 18 years of age. (Category B)” [6] The motion was passed, 14 to 1.